# Clinical Validation Plan

**Document Version:** 1.0  
**Last Updated:** 2026-02-14

---

## Objectives

- Measure sensitivity and specificity vs. gold standard (developmental-behavioral pediatrician, ASQ-3)
- Demonstrate safety for CDS use

---

## Study Design

- **Type:** Multi-site pilot
- **Cases:** 1,000+ with paired AI output and clinician assessment
- **Inclusion:** Ages 0â€“72 months, screening-appropriate
- **Exclusion:** Missing consent, incomplete data

---

## Endpoints

- Primary: Sensitivity for refer, specificity
- Secondary: PPV, NPV, calibration

---

## Safety Measures

- Immediate clinician notification for refer flags
- Conservative thresholds to minimize false negatives
- Data monitoring committee (DMC) for oversight

---

## DMC Roles

- Review adverse events, performance by slice
- Recommend study modifications if needed
